KLOFARABİN+ARA-C PROTOKOLÜ

Kaynaklar:

1- Scappini B, Gianfaldoni G, Caracciolo F, et al. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol. 2012;87:1047–1051.

2- Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155:182–189.

3- Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28:549–555.

4- Roberts DA, Wadleigh M, McDonnell AM, et al. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015;39:204–210.

5- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines – Acute Myeloid Leukemia. V.1.2015. http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf Accessed August31, 2015.